Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for July, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- How to Invest in QE's Twilight
- RTI: Fed Keeps QE Pace Unchanged
- ETFs on the Move After Bernanke's Press Conference
- Roundtable Top Picks of the Week
- FED Front & Center Again
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- Your Next Stock Should Be Making New Highs
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SONIC FOUNDR | SOFO | 4.40% |
| SUPPORTCOM I | SPRT | 3.75% |
| UNISYS CORP | UIS | 3.31% |
| SHORETEL INC | SHOR | 3.22% |
| GREEN MOUNTA | GMCR | 3.13% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
French pharmaceutical company, Sanofi’s (SNY - Analyst Report) Animal Health division, Merial, recently announced that it will acquire a privately-held India-based company, Dosch Pharmaceuticals Private Limited. The deal is expected to close in the first half of 2013. The financial details of the deal were not disclosed.
Dosch Pharmaceuticals’ animal health business has more than 86 animal health therapeutics and nutritional feed supplements and other products.
We expect this deal to help Sanofi tap the Indian animal health market better. Sanofi estimates that the Indian animal health market will generate 2012 sales of €350 million, exhibiting double-digit growth year over year.
As a reminder, Merial was founded in 1997. It was a 50/50 joint venture between Merck & Co. (MRK - Analyst Report) and Sanofi. Sanofi acquired Merck’s 50% share in September 2009 for $4 billion (approximately €2.9 billion). Currently, it is a wholly owned division of Sanofi.
We note that Sanofi’s biggest challenge is the generic threat that is being faced by several of its products. The company lost approximately €2.2 billion in sales in 2011 due to genericization.
Sanofi is looking to combat the generic threat through inorganic growth. Moreover, Sanofi is introducing new products to counter the loss of revenues due to genericization of key drugs. We believe that the proposed acquisition of Dosch Pharmaceuticals is a step in that direction.
We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #3 Rank (Hold) in the short run.
Large-cap pharma stocks currently holding a Zacks #2 Rank (Buy) include companies like Novo-Nordisk (NVO - Analyst Report).
Get the full Analyst Report on SNY - FREE
Get the full Analyst Report on NVO - FREE
Get the full Analyst Report on MRK - FREE